SCHEDULE: Perceptive Advisors Discloses 7.3% Stake in SAB Biotherapeutics

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. reported a 7.3% beneficial ownership stake in SAB Biotherapeutics, Inc. common stock.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in SAB Biotherapeutics, Inc. (the "Issuer").
• The Reporting Persons collectively beneficially own 3,471,861 shares of SAB Biotherapeutics, Inc. Common Stock, representing 7.3% of the class.
• This ownership percentage is based on 47,606,851 outstanding shares of Common Stock as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 14, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds the 3,471,861 shares.
• Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors, leading to their deemed beneficial ownership.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable institutional investor like Perceptive Advisors is generally viewed positively, as it signals confidence in the company's value proposition. This type of filing, however, does not contain operational or financial performance data to assess the company's intrinsic health, hence a moderate positive score.

Positives

• A significant institutional investor, Perceptive Advisors, a prominent life sciences investment firm, has disclosed a 7.3% passive stake in SAB Biotherapeutics, indicating a vote of confidence in the company's prospects.
• The investment is classified as passive, suggesting a long-term holding strategy without immediate intent to influence control, which can provide stability.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Perceptive Advisors may increase investor confidence and potentially attract further institutional interest, positively impacting share price perception.
• Company Management: Awareness of a significant passive institutional holder may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The disclosure of a significant passive stake by Perceptive Advisors, a prominent life sciences investor, indicates institutional confidence in SAB Biotherapeutics. While this is a positive signal, the filing itself does not provide operational or financial performance details to warrant a 'buy' or 'sell' recommendation. It primarily confirms a notable institutional presence, suggesting a 'hold' for existing investors and a signal for potential new investors to conduct further due diligence into the company's fundamentals.

Keywords

SAB Biotherapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology